Humulin M3

Humulin M3 is a recombinant human insulin (rDNA) formulated for injection and marketed in the European Union. It contains insulin human as the active ingredient and is supplied as a sterile solution for intramuscular or subcutaneous administration. As a prescription‑only product, Humulin M3 is used to replace or supplement endogenous insulin in patients with diabetes mellitus, helping to regulate blood glucose levels through daily therapy.

Humulin M3 is indicated for the management of hyperglycemia in patients with diabetes.

- Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen. - Type 2 diabetes mellitus when diet, exercise, and oral agents do not achieve glycemic targets. - Adjunct therapy during periods of increased insulin demand, such as illness or surgery. - Use in combination with rapid‑acting insulin analogues for flexible dosing. - Pediatric patients with type 1 diabetes, as approved by local regulatory authorities.

Like all insulin preparations, Humulin M3 may cause adverse reactions, ranging from mild to severe.

Common: - Hypoglycemia, especially if meals are missed or dosing is excessive. - Injection‑site pain, redness, or swelling. - Lipohypertrophy at repeated injection sites. - Weight gain associated with improved glycemic control.

Serious: - Severe allergic reactions, including anaphylaxis or urticaria. - Hypokalemia or other electrolyte disturbances. - Edema or heart failure exacerbation in susceptible patients. - Persistent hyperglycemia indicating possible insulin resistance or dosing error. - Acute pancreatitis. - Vision changes due to rapid glucose shifts.

Healthcare providers should assess patient-specific factors before initiating Humulin M3 and monitor for safety concerns during therapy.

- Adjust dose in renal or hepatic impairment to avoid hypoglycemia. - Use caution in patients with a history of severe hypoglycemia unawareness. - Monitor blood glucose closely during pregnancy, illness, or changes in physical activity. - Evaluate for allergic reactions at the first sign of rash, swelling, or breathing difficulty. - Consider cardiovascular status, as rapid glucose shifts can affect heart function. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulin M3 can interact with other medicines, influencing glucose levels or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulin analogues without dose adjustment. - Beta‑blockers that may blunt hypoglycemia warning signs.

Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk. - Corticosteroids, which can raise blood glucose and require higher insulin doses. - Diuretics, particularly thiazides, that may affect electrolyte balance. - ACE inhibitors or ARBs, which may potentiate insulin sensitivity.